Abstract 1566MO
Background
Surgery is the main modality of cure for solid cancers and was prioritised to continue even during SARS-CoV-2 outbreaks. This study aimed to identify immediate areas for system strengthening by comparing the delivery of elective cancer surgery during COVID-19 in periods of lockdown versus light restriction.
Methods
This international, prospective cohort study enrolled patients with 15 cancer types who had a decision for surgery during the COVID-19 pandemic up to 31st August 2020. Average national Oxford COVID-19 Stringency Index scores were calculated for each patient during the period they were awaiting surgery, classified into light restrictions (index <20), moderate lockdowns (20-60), and full lockdowns (>60). The primary outcome was the non-operation rate (proportion of patients who did not undergo planned surgery). Cox proportional-hazards regression models were used to explore the associations between lockdowns and non-operation.
Results
From 20,006 patients (466 hospitals, 61 countries), 9.1% did not receive surgery after a minimum of 3-months’ follow up (median:23 weeks, IQR:16 to 30 weeks). Light restrictions were associated with a 0.6% non-operation rate, moderate lockdowns 5.5% (adjusted hazard ratio:0.81, 95% confidence interval 0.77-0.84, p<0.001), and full lockdowns with a 15.0% rate (HR:0.51, 0.50-0.53). In sensitivity analyses, this effect was independent of local SARS-CoV-2 rates. Each additional week in lockdown led to a 9% reduction in the likelihood in a patient undergoing their cancer operation. Frail patients, those with advanced cancer, and those in lower-income settings were particularly vulnerable to lockdown effects. Surgery beyond 12-weeks from diagnosis increased during lockdowns (9.1% in light restrictions, 10.4% moderate lockdowns, 23.8% full lockdowns).
Conclusions
Cancer surgery systems worldwide were fragile to lockdowns, with one in seven patients not undergoing planned surgery and more preoperative delays. During current and future periods of societal restriction, the resilience of elective surgery systems requires strengthening, which may include ring-fenced surgical units and critical care capacity.
Clinical trial identification
NCT04384926.
Editorial acknowledgement
Legal entity responsible for the study
COVIDSurg Collaborate, University of Birmingham, UK.
Funding
National Institute for Health Research (NIHR) Global Health Research Unit, the Association of Coloproctology of Great Britain and Ireland, Bowel and Cancer Research, Bowel Disease Research Foundation, Association of Upper Gastrointestinal Surgeons, British Association of Surgical Oncology, British Gynaecological Cancer Society, European Society of Coloproctology, Medtronic, NIHR Academy, Sarcoma UK, The Urology Foundation, Vascular Society for Great Britain and Ireland, and Yorkshire Cancer Research.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1562MO - Effectiveness of COVID-19 vaccination in cancer patients: A nationwide Veterans Affairs study
Presenter: Julie Wu
Session: Mini oral session - SARS-CoV-2 and cancer
Resources:
Abstract
Slides
Webcast
1563MO - CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity
Presenter: Radka Obermannova
Session: Mini oral session - SARS-CoV-2 and cancer
Resources:
Abstract
Slides
Webcast
1564MO - Characterization of COVID-19 vaccination response by antibody (Ab) titer and T-cell receptor (TCR) sequencing in patients (pts) with advanced genitourinary (GU) cancers
Presenter: Sabrina Salgia
Session: Mini oral session - SARS-CoV-2 and cancer
Resources:
Abstract
Slides
Webcast
LBA60 - Prospective data of >20,000 hospitalised patients with cancer and COVID-19 derived from the International Severe Acute Respiratory and emerging Infections Consortium WHO Coronavirus Clinical Characterisation Consortium: CCP-CANCER UK
Presenter: Tom Drake
Session: Mini oral session - SARS-CoV-2 and cancer
Resources:
Abstract
Slides
Webcast
1565MO - Time-dependent improvement in the clinical outcomes from COVID-19 in cancer patients: An updated analysis of the OnCovid registry
Presenter: David Pinato
Session: Mini oral session - SARS-CoV-2 and cancer
Resources:
Abstract
Slides
Webcast
1567MO - COVID-19 and cancer: First report of the ESMO international, registry-based, cohort study (ESMO CoCARE)
Presenter: Emanuela Romano
Session: Mini oral session - SARS-CoV-2 and cancer
Resources:
Abstract
Slides
Webcast
Discussion 1562MO, 1563MO and 1564MO
Presenter: Luís Castelo-Branco
Session: Mini oral session - SARS-CoV-2 and cancer
Resources:
Slides
Webcast
Discussion LBA60, 1565MO, 1566MO and 1567MO
Presenter: Petros Grivas
Session: Mini oral session - SARS-CoV-2 and cancer
Resources:
Slides
Webcast